Free Republic 4th Qtr 2024 Fundraising Target: $81,000 Receipts & Pledges to-date: $11,664
14%  
Woo hoo!! And our first 14% is in!! Thank you all very much!! God bless.

Keyword: aorticvalve

Brevity: Headers | « Text »
  • Anyone here had open heart surgery(vanity)

    05/11/2024 12:28:02 AM PDT · by eastforker · 71 replies
    me ^ | 5/11/24 | me
    Just wanted to touch base with anyone that has had open heart surgery and what I can expect post surgery. I understand they want to replace my aortic valve, have had a heart murmur for many years and I guess it has gotten worse. Bless the VA because there is no way I could afford this any other way.
  • 'Ross procedure' leads to improved survival in adults undergoing aortic valve surgery (Provides normal life expectancy - “A huge deal”)

    02/23/2022 4:54:34 PM PST · by ConservativeMind · 10 replies
    The "Ross procedure" may be a more favorable option for aortic valve replacement among patients under 50 years old than more standard mechanical or biological replacements. The research is the first to compare the Ross procedure to the other options, and shows that it leads to improved survival and better outcomes in younger adults. "Not only was survival better than after biological or mechanical aortic valve replacement, it was also identical to the matched U.S. general population. To this day, this is the only operation that has ever been shown to restore survival after aortic valve replacement in young adults,"...
  • TAVR compared to SAVR in intermediate risk patients with aortic stenosis

    12/02/2017 9:01:27 AM PST · by Utah Binger · 22 replies
    News Medical Life Sciences ^ | November 1, 2017 | Dr. David J. Cohen
    Analysis of the PARTNER 2A trial and the SAPIEN-3 Intermediate Risk registry found transcatheter aortic valve replacement (TAVR) to be highly cost-effective compared with surgical aortic valve replacement (SAVR) in intermediate surgical risk patients with aortic stenosis. Findings were reported today at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. Researchers led by Dr. David J. Cohen (Saint Luke's Mid America Heart Institute, Kansas City, MO) used data from the PARTNER 2A randomized trial and the SAPIEN-3 Intermediate Risk registry...